EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases
EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases
June 2017
- A 61-year-old Caucasian woman presented with persistent cough and shortness of breath
- Patient history:
- Never smoked
- Mild hypertension, controlled on diuretic
- No major cardiovascular disease or diabetes
- Worked at local jazz club until symptoms forced her to resign
- Physical exam and imaging:
- No palpable masses
- CT reveals multiple tumors in right lung and brain metastases
- ECOG PS: 1
- Biopsy and mutation analysis:
- Adenocarcinoma
- EGFRexon 19 deletion
- No ALK rearrangement
- Started treatment with afatinib 40 mg once daily
- Developed diarrhea that necessitated dose interruption
- Recovered and resumed treatment at 30 mg once daily
March 2018
- Patient remains on afatinib, with no apparent progression
Related Videos
Related Content
FDA Grants Breakthrough Therapy Designation to Sunvozertinib in EGFR Exon20+ NSCLC
April 9th 2024Article
Sunvozertinib was granted breakthrough therapy designation by the FDA for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer harboring an EGFR exon 20 insertion mutation.
Read More
